Neurology
Found 8 results
Filters: Author is Perumal, Jai S and Keyword is Humans  [Clear All Filters]
2022
Marcille M, Rúa SHurtado, Tyshkov C, Jaywant A, Comunale J, Kaunzner UW, Nealon N, Perumal JS, Zexter L, Zinger N et al..  2022.  Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis.. Sci Rep. 12(1):4411.
2018
Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS.  2018.  Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.. Mult Scler. 24(4):540-542.
Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS.  2018.  Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.. J Neurol. 265(5):1226-1229.
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT et al..  2018.  Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.. N Engl J Med. 379(9):846-855.
Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS.  2018.  Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.. Mult Scler. 24(4):553-554.
2017
Al-Kawaz M, Monohan E, Morris E, Perumal JS, Nealon N, Vartanian T, Gauthier SA.  2017.  Differential Impact of Multiple Sclerosis on Cortical and Deep Gray Matter Structures in African Americans and Caucasian Americans.. J Neuroimaging. 27(3):333-338.
2013
Reardon J, Perumal JS.  2013.  Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.. Drug Des Devel Ther. 7:1187-93.
2012
Perumal JS, Foo F, Cook P, Khan O.  2012.  Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.. Mult Scler. 18(8):1197-9.